Previous 10 | Next 10 |
Image source: The Motley Fool. AtriCure Inc (NASDAQ: ATRC) Q4 2019 Earnings Call Feb 18, 2020 , 4:30 p.m. ET Operator Continue reading
AtriCure (NASDAQ: ATRC ): Q4 Non-GAAP EPS of -$0.37 beats by $0.03 ; GAAP EPS of -$0.42 in-line. More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
2019 Worldwide revenue of $230.8 million – an increase of 14.5% year over year 2019 U.S. revenue of $185.8 million – an increase of 14.6% year over year 2019 International revenue of $45.0 million – an increase of 13.9% year over year AtriCure, Inc . ( N...
BTIG Research has restarted coverage on the following: More news on: Abbott Laboratories, Abiomed, Inc., AtriCure, Inc., Healthcare stocks news, , Read more ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming SVB Leerink 9 th Annual Global Healthcare Conference in New York Cit...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2019 financial results on Tuesday, February 18, 2020. AtriCure will host a ...
AtriCure (NASDAQ: ATRC ) expects $61.3M in Q4 revenue (+16% Y/Y) with U.S. revenue of $49.5M and $11.8M in international sales. More news on: AtriCure, Inc., Healthcare stocks news, Read more ...
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quarter and full year 2019 and provided 2020 financial guidance. Preliminary, unau...
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the successful completion of patient enrollment in the aMAZE™ clinical trial. In addition, the company announced that it has rece...
The SPDR S&P 500 Trust's (SPY) rally to new highs has been a boon to big-cap investors, but the Russell 2000 has yet to eclipse its 2018 highs, and that's left small-cap investors envious. Fortunately, small caps' under-performance may not last much longer. Over the past decade, the Russel...
News, Short Squeeze, Breakout and More Instantly...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval from the National Medical Products A...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2024 financial results on Tuesday, Ju...